Articles On Pharmaust (ASX:PAA)

The ASX200 has slipped more than .3 of a per cent in early trade. And that’s a performance that’s slightly better than futures had suggested. Inflation data in this morning shows China’s economy remained stagnant in September with no cha...

PharmAust (ASX:PAA) wraps up cohort four of its phase one MEND study using MPL at 10 mg/kg to treat MND The study is supported by Australia’s largest independent not-for-profit organisation for MND research, FightMND PAA is using the...

Perth-headquartered clinical-stage biotechnology company PharmAust (ASX: PAA) has achieved a significant milestone with the final dosing of patients participating in the assessment of a treatment for the fatal motor neurone disease (MND/ALS...

PAA has finished does all patients in cohort 4 of its phase 1 study in MND/ALS Data from phase 1 expected in Q1 CY24 before a phase 2 trial commences Phase 1 data will support US orphan drug designation application MND/ALS addressable mark...

PharmAust (ASX:PAA) has announced positive top-line data from its Phase 2 veterinary clinical study of monepantel for the treatment of canine B-Cell lymphoma.

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader...

Determination of a clinically safe and efficacious dosing regimen of monepantel (MPL) for the treatment of dogs with B-Cell Lymphoma Treatment with MPL was safe, well-tolerated and there were no treatment-related deaths or severe adverse r...

PharmAust (ASX: PAA) has confirmed positive top-line data from a Phase 2 veterinary clinical study of its lead candidate monepantel (MPL) for the treatment of canine B-cell lymphoma. The study aimed to determine a clinically-safe and effica...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

New chief executive has experience executing clinical studies Dr Thurn was formerly part of the TGA’s Drug Safety Evaluation Branch Progress continues to be made on MND and canine cancer trials   PharmAust is strengthening its management...

PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company reports he has extensive experience in drug discovery, regulation and clinical trials Dr Roger Aston will remain as Chair, but transition i...

Clinical-stage biotechnology company investigating unique treatments for both humans and animals PharmAust (ASX: PAA), has chosen a highly experienced industry specialist with a wide range of skills to lead it through its next growth phase....

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust’s Phase 1 trial of lead drug candidate MPL shows positive signs of slowing MND/ALS progression There are currently no effective treatments to reverse progression of this invariably fatal disease PharmAust expects that MPL could...

PharmAust (PAA) reveals its phase one trial using MPL for MND and ALS has slowed disease progression in 11 out of 12 patients Analysis shows Nfl protein concentrations in the plasma of blood do not increase following MPL treatment, an in...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

An interim analysis of data from a Phase 1 clinical trial of PharmAust’s (ASX: PAA) lead drug candidate monepantel (MPL) has shown that neurofilament light chain (Nfl) protein concentrations in patient plasma do not increase following treat...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust is inching ever closer towards a Phase-2 clinical trial of its lead drug candidate monepantel (MPL) in people with Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS), after completing an interim pharmacokinetic analysis...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

PharmAust (PAA) appoints liquidators from Grant Thornton Australia to administer the creditor’s voluntary winding-up proceedings for PAA’s subsidiary, Epichem Epichem did not receive a new contract from DNDI, cutting funding into develop...

PharmAust (ASX:PAA) has completed its third cohort of six participants in the Phase 1/2 clinical trial of its lead drug candidate, monepantel, in Motor Neurone Disease.

PharmAust continues to progress the use of its lead drug candidate monepantel (MPL) in motor neurone disease closer to the Phase 2 clinical trial with the successful completion of the third patient cohort. With the successful completion of...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust continues to progress the Phase 2 trial of lead drug monepantel (MPL) in dogs with B-cell lymphoma and there are clear signs it is meeting its objectives. The trial, which is aimed at proving that MPL can improve quality of life,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust’s (PAA) patient, Louie the Beagle, surpasses one year of treatment with the company’s Monepantel (MPL) drug The clinical-stage biotechnology company reported the “significant milestone” for its patient in the phase two trial fo...

Imricor jumps 13pc after securing $30m in funding Singular Health signs a master distribution agreement in the US Louie the Beagle has passed the 1-year mark taking PharmAust’s Monepantel Imricor jumps 13pc on funding deal Imricor Medica...

PharmAust (ASX:PAA) has provided an update on the pharmacodynamic data from the Phase 1/2 trial of its lead drug candidate, monepantel in Motor Neurone Disease.

PharmAust (PAA) releases preliminary data from its phase 1/2 trial assessing monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS) Data showed that the suppression of inflammation could be responsible for slowing do...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust (PAA) announces that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of MPL in MND and ALS The trials are designed to test the tolerability, safety, pharmacokinetics and prelim...

PharmAust has announced that all 12 patients in Cohort 3 of its Phase-1/2 clinical trial of its lead drug candidate monepantel (MPL) in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS) have now received an initial, escalated do...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

PharmAust (ASX:PAA) has announced the commencement of Cohort 3 dosing in its current phase 1/2 trial, testing the effects of Monepantel (MPL) in individuals living with motor neurone disease.

Following the recent promotion of patients in Cohort 1 to Cohort 3, individuals will now receive a larger 6mg/kg dose of Monepantel treatment to combat motor neurone disease. In line with expectations, PharmAust (ASX:PAA) says Monepantel (...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...